In chronic inflammatory diseases, the endothelium is an attractive target for pharmacological intervention because it plays an important role in leukocyte recruitment. Hence, inhibition of endothelial cell activation and consequent leukocyte infiltration may improve therapeutic outcome in these diseases. We report on a drug targeting strategy for the selective delivery of the antiinflammatory drug dexamethasone to activated endothelial cells, using an E-selectin-directed drug-Ab conjugate. Dexamethasone was covalently attached to an anti-E-selectin Ab, resulting in the so-called dexamethasone-anti-E-selectin conjugate. Binding of the conjugate to E-selectin was studied using surface plasmon resonance and immunohistochemistry. Furthermore, internalization of the conjugate was studied using confocal laser scanning microscopy and immuno-transmission electron microscopy. It was demonstrated that the dexamethasone-anti-E-selectin conjugate, like the unmodified anti-E-selectin Ab, selectively bound to TNF-␣-stimulated endothelial cells and not to resting endothelial cells. After binding, the conjugate was internalized and routed to multivesicular bodies, which is a lysosome-related cellular compartment. After intracellular degradation, pharmacologically active dexamethasone was released, as shown in endothelial cells that were transfected with a glucocorticoid-responsive reporter gene. Furthermore, intracellularly delivered dexamethasone was able to down-regulate the proinflammatory gene IL-8. In conclusion, this study demonstrates the possibility to selectively deliver the anti-inflammatory drug dexamethasone into activated endothelial cells, using an anti-E-selectin Ab as a carrier molecule. The Journal of Immunology, 2002, 168: 883-889.
C
hronic inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and asthma are commonly characterized by an abundant leukocyte infiltration in the affected tissue. Present available therapies often aim at inhibition of the activity of the leukocytes, to reduce the harmful infiltration (1, 2) . However, the side effects of these fairly unspecific drugs as well as the nonresponsiveness of patients to treatment often limit the success of long-term therapy (3, 4) . Therefore, current efforts aim at developing new therapeutic strategies to treat these chronic inflammatory diseases in a more specific manner, as exemplified by the blockade of TNF-␣ in arthritis, psoriasis, and Crohn's disease (5) (6) (7) .
The endothelium is an attractive target for pharmacological intervention in chronic inflammation, because it plays an important role in leukocyte recruitment and infiltration (8) . Once activated, endothelial cells express adhesion molecules on their surface and secrete a broad variety of cytokines and chemokines, thereby directing the multistep adhesion cascade of leukocytes into inflamed tissue (9) .
To reduce leukocyte recruitment, Abs that block endothelial adhesion molecules have been therapeutically applied (10 -12) . These strategies are not always successful, possibly due to redundant leukocyte recruitment mechanisms in the body. Alternatively, selective inhibitors of cellular activation pathways have been developed, which, for example, reduce adhesion molecule and cytokine expression in endothelial cells (13, 14) . However, the in vivo use of these inhibitors is limited due to the importance of these activation pathways in other cells and processes in the body.
In the strategy described in this report, a so-called drug targeting approach is applied in which an Ab to E-selectin (CD62E) is used to deliver the covalently coupled anti-inflammatory drug dexamethasone into activated endothelial cells. The ultimate goal of this drug targeting approach is to selectively block endothelial cell activation at the site of inflammation. It is anticipated that the low drug concentrations in other cell types in the body will simultaneously diminish drug-associated side effects (15) .
In the present study, binding, uptake, and intracellular routing of an immunoconjugate consisting of the glucocorticoid dexamethasone covalently attached to an Ab recognizing E-selectin was investigated in HUVECs. Additionally, the pharmacological effect of the intracellularly delivered dexamethasone was determined using glucocorticoid reporter gene transfected endothelium as well as IL-8 Northern blotting. In this way, we investigated whether the immunoconjugate can be used for selective delivery of antiinflammatory drugs into activated endothelial cells.
Ab hEsel was purified from the culture medium by protein A affinity chromatography (protein A-Sepharose fast flow; Pharmacia, Roosendaal, The Netherlands) followed by dialysis against PBS. The 10E9 (rat anti-mouse E-selectin) mAb-producing hybridoma (Ab mEsel ) was kindly provided by Dr. D. Vestweber (Institute of Cell Biology, ZMBE, University of Münster, Münster, Germany). Ab mEsel was purified from the culture medium by protein G affinity chromatography (protein G-Sepharose fast flow; Pharmacia) followed by dialysis against PBS. An irrelevant control Ab (MOC31, mouse anti-human EGP-2 (Ab Ctrl )) was kindly provided by IQProducts (Groningen, The Netherlands).
The anti-dexamethasone polyclonal Ab was prepared in our laboratory (16) and was purified by absorption to polyvinylidene difluoride membranes coated with ␣-tocopherol-succinate-BSA (prepared similarly as dexamethasone (dexa)-Ab hEsel (described below), using 10 equivalents of ␣-tocopherol-succinate and one equivalent BSA). This procedure was performed to remove Abs recognizing the succinate linker in the conjugate. As a result, only Abs recognizing conjugated dexamethasone remained in the antiserum.
Human E-selectin/IgG fusion protein was kindly provided by Dr. J. van Dijk (Vrije Universiteit, Amsterdam, The Netherlands); human P-selectin/IgG fusion protein was kindly provided by Dr. B. Appelmelk (Vrije Universiteit).
Preparation of dexa-Ab conjugates
All chemicals used for preparation of the conjugates were of analytical reagent grade or higher. Dexamethasone (Bufa, Hilversum, The Netherlands) was conjugated via a succinate linker to the Ab according to Melgert et al. (16) (Fig. 1A ). For this, dexamethasone-21-hemisuccinate (dexa-suc) was prepared by reacting dexamethasone with succinic anhydride according to McLeod (17) with minor modifications. Briefly, dexamethasone (2.5 mmol), excess succinic anhydride (42 mmol), and 4-dimethylaminopyridine (2.6 mmol) were dissolved in 80 ml of anhydrous acetone and allowed to react for 24 h at room temperature. After removal of the solvent by evaporation under reduced pressure, the crude product was recrystallized from ethanol:water (3:7). The identity of the synthesized dexa-suc was confirmed by mass spectrometry (molecular mass, 492.5 Da; molecular mass found, 492.1 Da).
Dexa-Ab conjugates were prepared by activation of the carboxylic acid group of dexa-suc and subsequent reaction to primary amino groups of the Ab. Typically, dexa-suc (3 mol) dissolved in 300 l of 1,4-dioxane, tri-N-butylamine (16 mol) and isobutyl chlorocarbonate (15 mol) were allowed to react for 30 min at room temperature. A 5.2-l aliquot of this solution (corresponding to 52 nmol dexa-suc) was slowly added to a stirred solution of Ab (13 nmol, 0.5 mg/ml) in PBS. The mixture was stirred at room temperature for 4 h, after which the product was purified by dialysis against PBS at 4°C. The final product was filtered through a 0.2-m filter and stored at Ϫ20°C.
Characterization of dexa-Ab conjugates
Dexa-Ab conjugates were analyzed for protein content according to Lowry (18) . Dexamethasone content was analyzed by HPLC using a chromatography system consisting of a Waters 600 controller, 717plus autosampler and 486 tunable absorbance detector, operated at 240 nm, in combination with a Bondapak C18 guard-pak precolumn and a Bondapak C18 column (300 ϫ 3.9 mm) (all from Waters, Milford, MA). Elutions were performed with a water/acetonitrile/trifluoroacetic acid mixture (60/40/0.05) at a flow rate of 1.5 ml/min. Dexamethasone and dexa-suc eluted at 5.8 and 9.3 min, respectively.
The amount of coupled dexamethasone was analyzed after alkaline hydrolysis of the succinate linker during 1 h, followed by neutralization of the pH and direct analysis of released dexamethasone. For this, 20 l of the dexa-Ab solution was treated with 50 l of 0.1 N NaOH, mixed and incubated at room temperature for 1 h. After addition of 50 l of 0.1 N HCl and mixing, 30 l of the solution was injected into the HPLC.
SDS-PAGE analyses were performed on a mini-PROTEAN II system (Bio-Rad, Veenendaal, The Netherlands) using 7.5% polyacrylamide TrisHCl gels. Gels were either stained for protein (Coomassie brilliant blue staining) or blotted on polyvinylidene difluoride membrane, followed by immunostaining for conjugated dexamethasone.
Binding of dexa-Ab hEsel to E-selectin in a surface plasmon resonance study
A BIAcore 2000 instrument (Biacore, Uppsala, Sweden) was used to analyze the interaction between dexa-Ab hEsel and human E-selectin. All experiments were performed at 20°C using PBS containing 0.005% Tween 20. IgG fusion proteins (E-selectin, P-selectin) were immobilized on a CM5 sensor chip according to the manufacturer's instructions.
Binding interaction of Ab hEsel or dexa-Ab hsel with human E-selectin was determined by passing a cycle of five injections over the immobilized E-selectin chimeric protein at a flow rate of 30 l/min: 1) running buffer, 2) solution containing the primary ligand (either dexa-Ab hEsel or Ab hEsel , both at a concentration of 500 nM in running buffer), 3) running buffer, 4) solution containing the secondary ligand (anti-dexamethasone polyclonal antiserum diluted in running buffer), and 5) running buffer. At the end of each cycle, the sensor chips were regenerated with 0.1 M HCl and equilibrated with running buffer. Sensorgrams were corrected for background by baseline subtraction using an empty flow channel. Data were analyzed using BIAevaluation software (V2.1, Pharmacia Biosensor, Uppsala, Sweden).
Endothelial cells
HUVECs were isolated and cultured as previously described (19) and obtained from the Endothelial Cell Facility Groningen University/Academic Hospital Groningen (Groningen, The Netherlands). Primary isolates were cultured on 1% gelatin-precoated tissue culture flasks (Costar, Cambridge, MA) at 37°C under 5% CO 2 /95% air. The culture medium consisted of RPMI 1640 supplemented with 20% heat-inactivated FCS, 2 mM L-glutamine, 5 U/ml heparin, 100 U/ml penicillin, 100 g/ml streptomycin, and 50 g/ml endothelial cell growth factor supplement extracted from bovine brain. The H5V mouse endothelioma cell line was kindly provided by Dr. A. Vecchi (Istituto Ricerche Farmacologische Mario Negri, Milan, Italy). These cells were grown in tissue culture flasks at 37°C under 5% CO 2 /95% air. The culture medium consisted of DMEM supplemented with 10% heatinactivated FCS, 2 mM L-glutamine, and 300 g/ml gentamicin.
Both cell types, upon confluence, were detached from the surface by trypsin/EDTA (0.5/0.2 mg/ml in PBS) and split at a 1:3 ratio. For the experiments described, HUVEC were used up to passage three.
Analysis of binding of dexa-Ab conjugates to endothelial cells
Binding of dexa-Ab conjugates to endothelial cells was investigated using both immunohistochemistry and flow cytometry. HUVECs were grown to confluence on gelatin-precoated six-well-plates and stimulated with 100 ng/ml recombinant human (rh)TNF-␣ (Boehringer Mannheim, Mannheim, Germany) for 4 h. After three washes with cold PBS, cells were trypsinized and for immunohistochemical analysis spun down on slides using the Shandon Cytospin 3 Cell Preparation System (Life Sciences International, Veldhoven, The Netherlands). Cytospots were acetone-fixed, preincubated with 10% normal goat serum, and subsequently incubated with 10 g/ml dexa-Ab for 1 h at room temperature in a humid chamber. After extensive washing with PBS, Ab was detected by incubation with HRP-conjugated goat anti-mouse IgG (DAKO, Glostrup, Denmark), whereas conjugated dexamethasone was detected by rabbit anti-dexamethasone antiserum, followed by HRP-conjugated goat anti-rabbit IgG (DAKO). After color development counterstaining was performed with Mayers' hematoxylin and slides were mounted with glycerin.
For flow cytometry, trypsinized cells were incubated with 10 g/ml dexa-Ab hEsel or unconjugated Ab hEsel in 5% FCS/PBS for 1 h at 4°C. Ab was subsequently detected using FITC-labeled rabbit anti-mouse F(abЈ) 2 (DAKO, Glostrup, Denmark) and samples were analyzed using a Coulter Epics-Elite flow cytometer (Coulter Electronics, Hialeah, FL).
Data were analyzed using WinList (version 3D; Verity Software House, Topsham, ME) and WinMDI (version 2.8; The Scripps Research Institute, La Jolla, CA) software.
Internalization of dexa-Ab conjugates by endothelial cells
Internalization of dexa-Ab conjugates by endothelial cells was studied using confocal laser scanning microscopy (CLSM) and immuno-transmission electron microscopy (immuno-TEM).
HUVECs were grown to confluence on fibronectin-coated chamber slides (Lab-Tek; Nalge Nunc International, Naperville, IL) or gelatincoated flat-bottom 48-well plates for CLSM or immuno-TEM experiments, respectively. Cells were stimulated with 100 ng/ml rhTNF-␣ for 4 h. After 4 h, dexa-Ab was added to the medium to a final concentration of 10 g/ml. After various incubation periods, cells were washed with cold PBS and fixed with 2% paraformaldehyde/PBS overnight at 4°C.
CLSM
For detection of the localization of the conjugate by CLSM, cells were preincubated with 10% normal goat serum followed by permeabilization of the cells with 0.1% saponin in PBS. After permeabilization, Ab and conjugated dexamethasone were detected by, respectively, incubation with tetramethyl rhodamine-labeled goat anti-mouse IgG (Southern Biotechnology Associates, Birmingham, AL), and rabbit anti-dexamethasone antiserum followed by incubation with cyanine dye 5-labeled goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA).
Slides were embedded in antifading medium consisting of 0.25% Dabco (1,4-diazabicyclo[2.2.2]octane; Merck, Darmstadt, Germany) in glycerol/ PBS (9/1 v/v). Slides were examined using a confocal laser-scanning microscope equipped with a 488-nm argon, 568-nm krypton, and 647-nm HeNe laser (Leica TCS-SP; Leica Microsystems, Rijswijk, The Netherlands). Images were analyzed using Leica TCS-SP Power Scan software.
Immuno-TEM
For detection of Ab, cells were incubated with goat anti-mouse IgG labeled with 6 nm of colloidal gold (Aurion, Wageningen, The Netherlands). For localization of conjugated dexamethasone, cells were incubated with rabbit anti-dexamethasone followed by incubation with goat anti-rabbit IgG labeled with 6 nm of colloidal gold (Aurion). All Abs were dissolved in 1% BSA/PBS containing 0.05% Triton X-100. Cells and Abs were fixed with 2% glutaraldehyde/PBS for 15 min at room temperature. After several washes with water, silver enhancement was performed for 5 min to increase average gold particle size (R-gent; Aurion). Cells were washed with distilled water and fixed in 2% glutaraldehyde/PBS. Specimens were postfixed in 1% OsO 4 for 2 h and dehydrated with increasing alcohol concentrations, followed by propylene oxide. Thereafter, cells were embedded in Epon 812 (Serva, Heidelberg, Germany). Ultrathin sections (80 nm) were stained with uranylacetate and lead citrate and examined by use of a Philips 210 transmission electron microscope (Philips, Eindhoven, The Netherlands) at 60 kilovolts.
Reporter gene analysis of dexamethasone release from a dexa-Ab mEsel conjugate
H5V mouse endothelioma cells were transfected with lipoplexes containing the synthetic amphiphile Saint2 (Saint, Groningen, The Netherlands) and a reporter gene construct encoding glucocorticoid responsive element (GRE)-driven Firefly luciferase (Clontech Laboratories, Palo Alto, CA). The cells were cotransfected with pCMV-Luc encoding Renilla luciferase (Promega, Madison, WI) to correct for transfection efficiency. The molar ratio Firefly: Renilla DNA was 500:1 and the total amount of DNA used for transfection was 1 g. Twenty-four hours after transfection, rhTNF-␣ (250 ng/ml) was added in either the absence or presence of dexamethasone (1, 10, or 100 nM) or dexa-Ab mEsel (10 g/ml). Cells were harvested after 48 h and luciferase activity was measured using a Dual Luciferase Assay kit (Promega).
Down-regulation of IL-8 expression by dexa-Ab hEsel
HUVECs were grown to confluence on gelatin-precoated 25-cm 2 flasks and stimulated with 100 ng/ml rhTNF-␣. Where indicated, dexamethasone (100 nM) or dexa-Ab hEsel (10 g/ml) was added to the cells 1 h before or simultaneous with start of TNF-␣ stimulation, respectively. After 6 h of TNF-␣ stimulation, total RNA was extracted using TRIzol reagent (Life Technologies, Gaithersburg, MD). The amount of RNA extracted was measured by optical density at 260 nm. RNA (4 g) was separated on a 1% agarose/formaldehyde gel and blotted overnight onto Hybond N ϩ membrane (Boehringer Mannheim) in 10ϫ SSC (150 mM sodium chloride, 15 mM sodium citrate, pH 7.0).
32 P-labeled radioactive random-primed IL-8
and GAPDH probes were synthesized from PCR products, using the Strip-EZ DNA kit (Ambion, Austin, TX). According to Church and Gilbert (20) , the blot was hybridized with the IL-8 probe at 65°C and subsequently exposed to a phosphor imager screen. After removal of the radioactive probe from the membrane, according to the Strip-EZ protocol (Ambion), hybridization was repeated, this time using the random-primed GAPDH as a probe.
The obtained IL-8 and GAPDH signals were quantified using Storm 860 PhosphorImager (Molecular Dynamics, Sunnyvale, CA) and ImageQuant software (Molecular Dynamics).
Results

Preparation and characterization of dexa-Ab conjugates
Dexa-Ab hEsel conjugates were prepared by coupling dexa-suc to primary amino groups of the Ab (Fig. 1A) . SDS-PAGE followed by anti-dexamethasone Western blotting demonstrated that dexamethasone indeed had been covalently conjugated to the 150-kDa Ab (Fig.  1B) . To assess the amount of coupled dexamethasone molecules, the ester linkage between the drug and protein was chemically degraded and the amount of dexamethasone was determined by HPLC. The results of this analysis, in combination with the protein content of the conjugates, yielded an average dexamethasone content of 2.3 drug molecules per Ab hEsel molecule, i.e., 56% conjugation efficiency. Similar drug conjugation efficiencies were found for Ab Ctrl -and Ab mEsel -based drug-Ab conjugates.
Binding of dexa-Ab hEsel to E-selectin in a surface plasmon resonance study
The binding of dexa-Ab hEsel conjugate to immobilized human Eselectin/IgG chimeric protein was investigated using surface plasmon binding technology. In theory, the coupling of dexamethasone could disrupt the Ag recognition of Ab hEsel to human E-selectin. To discriminate between the binding of unmodified Ab hEsel and dexa-Ab hEsel , anti-dexamethasone was applied as a secondary ligand to the (dexa-)Ab hEsel molecules bound on the chip. The sensorgrams clearly showed binding of dexa-Ab Esel to E-selectin, as reflected by the secondary increase in the resonance signal upon incubation with the anti-dexamethasone Ab (Fig. 2) .
This indicated that indeed the dexamethasone-conjugated Ab was able to bind to E-selectin. Binding experiments on immobilized human P-selectin/IgG showed no binding of both Ab hEsel and dexa-Ab hEsel (Fig. 2) .
Analysis of binding of dexa-Ab conjugates to endothelial cells
We next addressed the question of whether dexa-Ab hEsel was also able to selectively bind to E-selectin expressed on the endothelial FIGURE 1. Synthesis and characterization of the dexamethasone-anti-E-selectin conjugate dexa-Ab hEsel . A, Schematic drawing of the preparation of dexa-Ab hEsel , indicating the biodegradable and nondegradable linkage between the dexamethasone and protein part of the conjugate. Note that, during degradation, the native dexamethasone molecule will be released. B, Protein staining and Western blot analysis of Ab hEsel and dexa-Ab hEsel showing a similar molecular mass for both the native protein and the conjugate. This implies that during synthesis no polymerization of the protein occurred. Reactivity of the dexa-Ab hEsel with the antidexamethasone Ab at the molecular mass of the Ab demonstrated covalent attachment of dexamethasone to the protein.
cell surface. The conjugate specifically bound to rhTNF-␣-stimulated HUVEC as shown by immunohistochemical analysis of the presence of both the Ab and the conjugated dexamethasone (Fig.  3, B and C) . As controls, dexa-Ab hEsel did not bind to resting HUVEC (Fig. 3A) , and dexa-Ab Ctrl did not bind to activated endothelial cells (Fig. 3D) .
Flow cytometry confirmed binding of dexa-Ab hEsel to trypsinized activated endothelial cells and not to resting endothelial cells (Fig. 3F) , similar to binding observed with unconjugated Ab hEsel (Fig. 3E) .
Internalization of dexa-Ab conjugates by endothelial cells
After binding, dexa-Ab Esel needs to be internalized by endothelial cells to be degraded, which is a prerequisite for dexamethasone to be released and to have a pharmacological effect. Using CLSM, we determined that dexa-Ab hEsel bound to and was internalized by HUVECs stimulated for 4 h with rhTNF-␣ (Fig. 4) . At this time point HUVEC had maximal expression of E-selectin on their surface (data not shown). After 1 h of incubation, a comparable staining pattern for Ab hEsel was found for both unmodified Ab hEsel and dexa-Ab hEsel (Fig. 4, A and D) .
In the case of dexa-Ab hEsel , conjugated dexamethasone could clearly be detected (Fig. 4E) , and this staining pattern colocalized completely with the staining for Ab hEsel (Fig. 4F) . This indicates that (part of) the dexamethasone molecules were still conjugated to Ab hEsel upon transport into the endothelium.
Initial binding at the cell surface was already seen at 10 and 20 min after conjugate incubation (Fig. 4, G and H) . Starting from 1 h after incubation, surface staining decreased and an intracellular, punctuate, vesicle-like staining pattern could be observed for both the dexamethasone and Ab hEsel part of the conjugate (Fig. 4, F and  I-L) . Staining intensities decreased after 18 -24 h of incubation (Fig. 4, K and L) , most likely indicating intracellular degradation of the conjugate. In control experiments, dexa-Ab hEsel was not internalized by resting HUVEC, nor was dexa-Ab Ctrl internalized by activated HUVEC, resulting in fully black images (data not shown).
Immuno-TEM studies were used to investigate the nature of the vesicle-like structures as detected by the CLSM studies. After 1 h of incubation, both the dexamethasone and Ab hEsel parts of the conjugate, although with a clear difference in quantity, localized at the cell membrane, in small vesicles just below the plasma membrane, as well as in multivesicular bodies (Fig. 5) . In time, cell membrane localization of the conjugate decreased, whereas accumulation in multivesicular bodies increased (data not shown). Lysosomes (in the definition of electron dense bodies), and hence the presence of the conjugate in lysosomes, were hardly observed in the endothelial cells.
As expected, neither dexamethasone nor Ab hEsel localized in the nucleus, indicating that the conjugated dexamethasone did not determine the intracellular routing of the conjugate. In accordance with the CLSM studies, internalization of dexa-Ab Ctrl could not be detected (data not shown).
Reporter gene analysis of dexamethasone release from dexa-Ab mEsel
After internalization and degradation, dexamethasone has to diffuse into the cytoplasm and bind to its receptor to be able to exert a pharmacological effect. In theory, upon binding of dexamethasone to the glucocorticoid receptor, the complex translocates to the nucleus where it binds to GREs in the DNA, as a result of which gene expression is affected. We measured this effect by analyzing the expression of a luciferase reporter gene that contains a GRE promoter. Because the primary cell type HUVEC was difficult to transfect (only ϳ2% transfection efficiency was obtained using the (A and B) or anti-dexamethasone staining (C and D) (original magnification, ϫ400). Flow cytometry was performed to compare the binding pattern of unconjugated Ab hEsel (E) to the binding pattern of dexa-Ab hEsel (F). Unconjugated and conjugated Ab hEsel selectively bound to activated HUVEC to a similar extent. Thin line, Binding of (dexa-) Ab hEsel to resting HUVEC; bold line, binding of (dexa-)Ab hEsel to activated HUVEC. For clarity, histograms of isotype control staining patterns are not depicted. These patterns are similar to the patterns seen with resting HUVEC, indicating absence of nonspecific binding.
protocol described in Materials and Methods), the mouse endothelioma cell line H5V was transfected with the GRE-luciferase plasmid (20 -25% transfection efficiency). This cell line expresses E-selectin after TNF-␣ stimulation, which is a prerequisite for testing E-selectin-directed conjugates.
After transfection, H5V cells were incubated with dexa-Ab mEsel (10 g/ml, corresponding to ϳ100 nM dexamethasone) and the GRE-mediated luciferase expression was compared with the expression obtained after incubation with 1, 10, and 100 nM unconjugated dexamethasone, respectively. GRE-mediated luciferase expression was measured in three independent experiments.
The result of one representative experiment is shown in Fig. 6 . Luciferase activity increased with increasing concentration of unconjugated dexamethasone. In all three experiments, the luciferase activity induced by dexa-Ab mEsel was comparable with the activity induced by unconjugated dexamethasone at a concentration between 1 and 10 nM. From this, it was concluded that dexa-Ab mEsel is indeed capable of delivering pharmacologically active dexamethasone into activated endothelial cells, although the amount of delivered dexamethasone is less than what enters the cell by passive diffusion of unconjugated dexamethasone.
Down-regulation of IL-8 expression by dexa-Ab hEsel
In our cellular system with the primary endothelial cell type HUVEC, no effects of freely administered dexamethasone on the expression of adhesion molecules VCAM-1 or ICAM-1 could be demonstrated. Therefore, to confirm pharmacological activity of intracellularly delivered dexamethasone, down-regulation of the proinflammatory gene encoding IL-8 was analyzed by Northern blotting. Incubation of HUVEC with TNF-␣ resulted in increased expression of IL-8 mRNA, which was partly down-regulated by coincubation with either free dexamethasone or dexa-Ab hEsel conjugate. Band intensities of IL-8, normalized to GAPDH mRNA expression levels, quantitatively demonstrated 28 and 22% decreases in IL-8 mRNA accumulation after treatment with 100 nM dexamethasone and 10 g/ml dexa-Ab hEsel conjugate, respectively (Fig. 7) . Similar decreases in IL-8 mRNA levels were observed using other techniques, including competitive RT-PCR and cDNA expression array analysis (S. A. Á sgeirsdóttir, R. Kok, M. Everts, D. Meÿer, and G. Molema, manuscript in preparation).
Discussion
In this study the cellular handling and intracellular routing was investigated of an E-selectin-directed immunoconjugate consisting of an anti-E-selectin Ab and the anti-inflammatory glucocorticoid dexamethasone. Furthermore, it was demonstrated that such a conjugate is able to selectively deliver dexamethasone into activated endothelial cells and not resting endothelial cells. The conjugate did not affect cellular integrity or viability because, in all experiments described, no effects on cellular morphology were observed.
E-selectin was chosen as a target molecule because this adhesion molecule is solely expressed on activated endothelial cells (21) , thus enabling selective delivery of the drug into this cell type. Furthermore, it is an internalizing adhesion molecule, in contrast with, e.g., the adhesion molecules ICAM-1 or VCAM-1 (22) . Internalization is an important quality of a target molecule because it is essential for intracellular degradation of the conjugate and hence release of the targeted drug. Detailed studies on targeting drugs to endothelial cells are scarce and, until now, they have mainly focused on the delivery of cytotoxic drugs (23) . However, in inflammation, killing of endothelial cells is not considered a rational strategy to achieve improved therapeutic outcome. Therefore, we aim at the downregulation of endothelial activation by selective delivery of anti-inflammatory drugs. Dexamethasone was chosen as a model drug because of its broad spectrum of pharmacological effects. Furthermore, a polyclonal anti-dexamethasone antiserum was available to study the fate of the conjugated dexamethasone during intracellular handling of the conjugate by the endothelium.
The surface plasmon resonance studies and cellular binding demonstrated that the dexa-Ab hEsel conjugate, with an average of two conjugated dexamethasone molecules per Ab, still recognized its target molecule. Higher dexamethasone loading ratios (up to 10 dexamethasone molecules per Ab Esel molecule) reduced the solubility of the conjugate and diminished the E-selectin recognition (data not shown). Because the conjugation of high amounts of dexamethasone may also result in an increased distribution of the conjugate to the liver in vivo (16), the dexa-Ab Esel conjugate with two molecules of dexamethasone per carrier molecule was used in the experiments described in this work. Hybridization signals of IL-8 mRNA were normalized to GAPDH mRNA concentrations. IL-8 expression in activated HUVEC was arbitrarily set at 100%. TNF-␣-up-regulated IL-8 mRNA levels were partly repressed by coincubation with free dexamethasone (100 nM) or dexa-Ab hEsel (10 g/ml). This decrease in IL-8 mRNA accumulation indicates that the intracellularly delivered dexamethasone was able to exert pharmacological activity similarly to free dexamethasone.
FIGURE 5.
Immuno-TEM analysis of the localization of dexa-Ab hEsel in activated HUVEC 1 h after incubation of the cells with the conjugate at a concentration of 10 g/ml. Staining for Ab hEsel (A) and conjugated dexamethasone (B). Both Ab hEsel and dexamethasone were present at the outer membrane (arrows), in vesicles (arrowheads), and in multivesicular bodies ‫,)ء(‬ although staining for Ab hEsel was more abundant than for dexamethasone. Detailed images of the presence of Ab hEsel at the outer membrane and vesicles (C) and in a multivesicular body (D), and of the presence of dexamethasone in a multivesicular body (E). Scale bar ϭ 1 m (A and B) or 500 nm (C-E). Our CLSM and immuno-TEM studies indicate that the dexaAb hEsel conjugate is intracellularly routed to vesicle-like structures, identified as multivesicular bodies. Because multivesicular bodies are lysosomal-related structures (24, 25) , these data are in agreement with other studies on the routing of an unmodified anti-E-selectin Ab, where a final lysosomal pathway of the Ab was indicated (22, 26) . Thus, the intracellular routing of the carrier Ab hEsel was not affected by conjugation of the anti-inflammatory drug dexamethasone.
The presence of dexa-Ab hEsel in multivesicular bodies and the absence of the conjugate in the nucleus is in contrast with the intracellular routing of a hydrocortisone-BSA conjugate (27) . This steroid-protein conjugate localized in the nucleus after binding to its hormone receptor in the target cells. A likely explanation of this discrepancy is the difference in the number of drug molecules conjugated to the carrier protein. Whereas the hydrocortisone-BSA conjugate contained 21 molecules of hydrocortisone per BSA molecule, Ab hEsel was modified with only two molecules of dexamethasone per Ab molecule.
Dexa-Ab Esel conjugates were prepared in which the drug molecule was coupled via a succinate linker to primary amino groups of the Ab. This succinate linkage is sufficiently stable to deliver dexamethasone to the intracellular compartments of the target cells where the conjugate is degraded (16, 17) . The pharmacologically active dexamethasone is subsequently released and can exert an effect, as shown by the reporter gene analysis in transfected endothelial cells. Despite the lower amount of drug delivered by dexaAb mEsel when compared with intracellular accessibility of free dexamethasone, the conjugate has the advantage over unconjugated dexamethasone of being selective in delivering the drug into activated endothelial cells. Drug-associated side effects in other cell types will thus be diminished.
Because the artificial read-out system, consisting of the GREluciferase reporter gene, does not reflect the physiological effects of delivered dexamethasone, effects of dexamethasone on proinflammatory IL-8 mRNA levels were characterized by Northern blotting. Results demonstrated the ability of selectively delivered dexamethasone to decrease proinflammatory gene expression in activated endothelial cells. To further extend analysis of pharmacological effects of dexamethasone, gene expression profiling was performed, using a human cDNA cytokine/receptor array. The observed changes in mRNA levels of various cytokines and related molecules support our data presented in this report that dexamethasone is released in a pharmacologically active form, once intracellularly delivered by the dexa-Ab hEsel conjugate (S.A. Á sgeirsdóttir, R. Kok, M. Everts, D. Meÿer, and G. Molema, manuscript in preparation).
In conclusion, the immunoconjugate dexa-Ab Esel was internalized and intracellularly degraded by activated endothelial cells, allowing the release of pharmacologically active dexamethasone. Therefore, this study shows the possibility of using an anti-E-selectin immunoconjugate to selectively deliver anti-inflammatory drugs into activated endothelial cells. Further in vivo evaluation will elucidate the potential of this drug targeting strategy to selectively interfere with endothelial cell activation and hence leukocyte recruitment in chronic inflammatory diseases.
